Biotech entity
Coverage clusters in pharma, which accounts for 6 of those 7, with the remainder spread across 1 other category. Negative sentiment reaches 0% here, compared with 18% across the 574-story beat baseline for the same window. Of the tracked stories, 3 of 7 also mention Royal Bank of Canada, the most common co-covered peer.
Last mentioned: Sep 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in pharma, which accounts for 6 of those 7, with the remainder spread across 1 other category. Negative sentiment reaches 0% here, compared with 18% across the 574-story beat baseline for the same window. Of the tracked stories, 3 of 7 also mention Royal Bank of Canada, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. That works out to roughly 0.3 stories per week across a 169-day span. At 5.4, the average consequence score sits below the same-window beat average of 6.1. We currently track 7 Biotech stories that mention Morgan Stanley, published between March 9, 2026 and August 24, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 574 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Morgan Stanley. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
Enveric reports quarterly loss
Enveric Biosciences reported EPS of -$0.76 for the quarter.
RBC raises CTNM target to $23
Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
Contineum reports Q2 results
Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
Weiss Ratings reiterates Sell ratings
Weiss Ratings restated a Sell (d-) on CTNM and a Sell (e+) on ENVB.
Morgan Stanley raises CTNM target
Morgan Stanley raised its price target on Contineum Therapeutics from $14.00 to $16.00 with an Equal Weight rating.
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Source: dailypolitical.com · themarketsdaily.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
A 114% short interest surge in Towa Pharmaceutical contrasts with a Morgan Stanley upgrade, spotlighting the tension between bearish OTC bets and fundamental analysis of Japan’s drug R&D landscape.
Source: themarketsdaily.com
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
Morgan Stanley’s divergent ratings on Charles River and IQVIA reflect how biotech funding cycles drive CRO demand. For biotech and pharma executives, the CRL upgrade signals that contract research capacity for preclinical and lab testing may tighten as capital flows back into early-stage drugmakers.
Source: Sacbee · Kansascity
A new Morgan Stanley report identifies 'affordability politics' as a primary risk for the pharmaceutical sector ahead of the 2026 midterm elections. The firm warns that targeted legislative measures to lower prescription drug costs could create significant pricing pressure on high-margin brand-name drugs.
Morgan Stanley is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
